Nanoprecise Sci Corp | $38,000,000 | (Mar 28, 2025)
Mendel | $35,000,000 | (Mar 28, 2025)
Galatea Bio Inc. | $25,000,000 | (Mar 28, 2025)
Certified by Founder
Lodge
Curevo Vaccine
start up
United States
- Bothell, Washington
- 19/03/2025
- Series B
- $110,000,000
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.
- Industry Biotechnology Research
- Website https://curevovaccine.com/
- LinkedIn https://www.linkedin.com/company/curevovaccine/
Related People
George SimeonFounder
United States -
Greater Seattle Area
Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution
MemryX Inc. | $44,000,000 | (Mar 28, 2025)
Mila Beauté | $2,160,000 | (Mar 28, 2025)
Lucky Beverage Co. | $14,200,000 | (Mar 28, 2025)
Taxo (YC S24) | $5,000,000 | (Mar 28, 2025)
BuildVision | $10,000,000 | (Mar 28, 2025)
Yutori | $15,000,000 | (Mar 28, 2025)
Nexthop AI | $110,000,000 | (Mar 27, 2025)
Topanga.io | $8,000,000 | (Mar 27, 2025)
Silna | $27,000,000 | (Mar 27, 2025)